Correspondence 0001683168-24-000338 from CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc.
Date: Jan. 18, 2024 · CIK: 0001729427 · Accession: 0001683168-24-000338
AI Filing Summary & Sentiment
File numbers found in text: 333-275973
Letter
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
January 18, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: CNS Pharmaceuticals, Inc.
Registration Statement on Form S-1 (the “Registration Statement”)
File No. 333-275973
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on January 16, 2024 regarding the acceleration of the effectiveness of the above-referenced Registration Statement to 5:00 P.M. (Eastern Time) on January 18, 2024. We hereby formally withdraw our prior request for acceleration of the effective date of such Registration Statement.
Very truly yours,
CNS Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 January 18, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-275973 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on January 16, 2024 regarding the acceleration of the effectiveness of the above-referenced Registration Statement to 5:00 P.M. (Eastern Time) on January 18, 2024. We hereby formally withdraw our prior request for acceleration of the effective date of such Registration Statement. Very truly yours, CNS Pharmaceuticals, Inc. By: /s/ Christopher Downs Name: Christopher Downs Title: Chief Financial Officer cc: Cavas Pavri, ArentFox Schiff LLP